ERBB2 and breast carcinoma: Finally, we did not observe an association of HER2DX prognostic risk-score with treatment response, confirming prior results20,23,24 where predictors of long-term outcome in early-stage HER2-positive breast cancer were found to be distinct from predictors of response to neoadjuvant anti-HER2-based treatments.